WuXi Biologics Maintains Top ESG Index Inclusions for 2026

  • WuXi Biologics included in Hang Seng ESG 50 Index and Hang Seng Corporate Sustainability Benchmark Index for 2026.
  • Company received A+ rating in HKQAA's 2026 sustainability assessment.
  • WuXi Biologics has over 1064 integrated client projects as of June 30, 2026.
  • CEO Dr. Chris Chen emphasizes sustainability as a cornerstone of long-term business growth.

WuXi Biologics' continued inclusion in top ESG indexes underscores the growing importance of sustainability in the biopharmaceutical industry. As ESG criteria become increasingly critical for investment decisions, the company's strong performance positions it favorably among peers. The recognition also highlights the strategic value of integrating sustainability into core operations, particularly in a sector facing heightened regulatory and stakeholder scrutiny.

Sustainability Leadership
How WuXi Biologics will leverage its ESG excellence to attract ESG-focused investors and clients.
Industry Benchmarking
Whether the company's A+ rating will set a new standard for ESG performance in the biopharmaceutical sector.
Operational Resilience
The pace at which WuXi Biologics can integrate sustainability into its global operations while maintaining efficiency.